Newron Pharmaceuticals SpA is a biopharmaceutical company based in Bresso, near Milan, Italy, with a dedicated focus on the research, development, and commercialization of novel therapies for patients suffering from diseases of the central nervous system (CNS) and pain. The company's core scientific mission is to address significant unmet medical needs in difficult-to-treat indications, such as Parkinson's disease and schizophrenia, where limited therapeutic innovation has been observed for decades. Newron operates an asset-centric model, concentrating its efforts on advancing a balanced and robust pipeline of drug candidates from discovery through clinical development, leveraging a proven track record of drug development and commercialization expertise. The firm often partners with specialized pharmaceutical companies for the late-stage development and commercialization of its compounds globally.
Products and Services
Newron Pharmaceuticals' offerings consist of a portfolio of pharmaceutical products, including one successfully commercialized asset and multiple drug candidates in various stages of clinical development. The company's services are primarily centered on proprietary scientific research and clinical development in the neuroscience and pain management therapeutic areas.
Commercialized Product
Xadago (Safinamide)
The company's key commercialized product is Xadago (safinamide), a compound developed as an adjunctive therapy for the treatment of Parkinson's disease.
Indication: Xadago is approved for use as an add-on treatment to a regimen that includes levodopa for mid- to late-stage fluctuating Parkinson's disease. It is utilized to help manage the motor fluctuations associated with the disease.
Mechanism of Action: Safinamide exhibits a dual mechanism of action. It functions as a potent, highly selective, and reversible inhibitor of monoamine oxidase B (MAO-B), which reduces the breakdown of dopamine in the brain. Crucially, it also blocks voltage-sensitive sodium channels and modulates the stimulated release of glutamate, offering both dopaminergic and non-dopaminergic benefits.
Commercialization Model: Newron has established international development and commercialization agreements for Xadago with partners, including Zambon for various territories, such as the European Union and Switzerland, and Meiji Seika Pharma Co., Ltd. for Japan and other key Asian territories. It is approved in numerous international markets, including the US, UK, and Japan, generating revenue for Newron through milestones and royalties.
Clinical Development Pipeline
Newron maintains a strong pipeline of innovative drug candidates aimed at addressing critical CNS disorders. The lead pipeline compounds are Evenamide, Ralfinamide, and Sarizotan.
Evenamide (NW-3509)
Evenamide is Newron???s lead compound and represents a potential new treatment paradigm in schizophrenia. It is currently in Phase III clinical development.
Indication: Evenamide is being developed as an add-on therapy to existing antipsychotics for two specific, difficult-to-treat patient populations: treatment-resistant schizophrenia (TRS) and chronic schizophrenia patients who show a poor response to standard treatment.
Mechanism of Action: This compound is a first-in-class, orally administered glutamate modulator. Its unique action involves the selective inhibition of voltage-gated sodium channels in hyper-active neurons. This modulation is intended to normalize glutamatergic dysfunction, a critical underlying pathology in patients who do not respond adequately to traditional antipsychotic medications. By reducing hippocampal and cortical hyper-excitability, Evenamide aims to restore neurophysiological balance without broadly interfering with numerous CNS receptors, enzymes, or transporters that are often targets of conventional antipsychotics.
Clinical Status: Clinical trial data, including from a one-year Phase II study, have demonstrated sustained, progressive, and clinically significant improvements in key efficacy measures, such as the Positive and Negative Syndrome Scale (PANSS), when Evenamide is added to current antipsychotic treatments, with a favorable safety profile. The company is advancing a global Phase III program for this compound.
Ralfinamide
Ralfinamide is another asset in Newron's pipeline, a compound with a mechanism of action involving the blockade of sodium channels.
Indication: The development of ralfinamide is focused on specific, rare pain indications, particularly neuropathic pain. The company is evaluating its potential for patients with pain conditions that are underserved by current treatments.
Sarizotan
Sarizotan represents Newron's focus on rare diseases with high unmet need.
Indication: Sarizotan is a drug candidate for the treatment of Rett syndrome, a severe neurodevelopmental disorder that primarily affects females.
Regulatory Status: The compound has received Orphan Drug Designation in both the European Union and the US, a status granted to drugs intended to treat rare conditions. The company has pursued studies aimed at bringing this potential therapy to patients with this debilitating condition.
Partnership and Scientific Research
Beyond its product pipeline, Newron's activities include ongoing proprietary scientific research to identify and develop new chemical entities for CNS and pain disorders. Its business model relies heavily on strategic partnerships, such as those with Zambon and Meiji Seika Pharma, to maximize the global market potential of its developed assets like Xadago and to co-develop pipeline compounds like Evenamide in certain territories. This collaborative approach is a key part of Newron???s service offering, ensuring novel treatments reach patients worldwide.
Please note: This information is generated by AI. For legal use, verify with company sources.
